You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity

Authors

  • Emmanuelle Moraes Ribeiro Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Kathy-Ann Secker Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Ana-Maria Nitulescu Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Rebekka Schairer Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Hildegard Keppeler Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Anton Wesle Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Hannes Schmid Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Anita Schmitt Department of Oncology, Hematology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Brigitte Neuber Department of Oncology, Hematology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Daniela Chmiest Department of Immunobiology, University of Lausanne, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Silvia Podavini Department of Immunobiology, University of Lausanne, Lausanne, Switzerland PubMed articlesGoogle scholar articles
  • Melanie Märklin Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, GermanyCluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Boris Klimovich Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Michael Schmitt Department of Oncology, Hematology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany PubMed articlesGoogle scholar articles
  • Fulya Korkmaz Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Claudia Lengerke Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Corina Schneidawind Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, GermanyDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland PubMed articlesGoogle scholar articles
  • Dominik Schneidawind Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, GermanyDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland PubMed articlesGoogle scholar articles

Citation

Moraes Ribeiro E, Secker K, Nitulescu A, et al
PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity
Journal for ImmunoTherapy of Cancer 2024;12:e007829. doi: 10.1136/jitc-2023-007829
Online issue publication 
March 20, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.